Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma
When treating advanced HCC, nivolumab and cabozantinib together have the ability to increase T lymphocyte numbers, reduce tumor marker levels, effectively prolong survival time, and have better efficacy than simple control treatment, with good safety.
Authors
- Lu-Wen Liang
- Rongkui Luo (ORCID: https://orcid.org/0000-0002-4118-7225)
- Zhi‐Li Huang (ORCID: https://orcid.org/0000-0001-9359-1150)
- Lina Tang (ORCID: https://orcid.org/0000-0001-7975-2472)
Institutions
- Army Medical University (CN)
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Third People 's Hospital of Chongqing (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2025-03-24
- DOI
- https://doi.org/10.4251/wjgo.v17.i4.103631
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64